Compare Ryanair Holdings plc (RYAAY) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ryanair Holdings plc vs BIO-TECHNE Corp — how do they compare? Ryanair Holdings plc trades at $54.16 (market cap $27.95B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: Ryanair Holdings plc is far larger — about 2.5× BIO-TECHNE Corp's market cap, and Ryanair Holdings plc pays the higher dividend (1.6%). Which is the better fit depends on your goals — on Pluang, investors hold Ryanair Holdings plc for 72 Days and BIO-TECHNE Corp for 63 Days on average.
| RYAAY | TECH | |
|---|---|---|
Market Cap | $27.95B | $11.37B |
Volume | 1,519,820 | 3,153,511 |
Sector | Industrials | Health |
52-Week High | $73.82 | $72.61 |
52-Week Low | $51.95 | $43.31 |
Typical Hold Time | 72 Days | 63 Days |
Enterprise Value | $25.00B | $11.40B |
Dividend Yield | 1.6% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RYAAY trades at $56.00 with a slight 0.24% daily gain, showing mixed technical signals amid bearish moving averages but neutral oscillators. Fundamentally, the airline maintains strong profitability with 12.13% net margins and attractive valuation multiples (P/E 13.95, EV/EBITDA 6.22), though recent Q3 2026 earnings are pending against high expectations. Analyst sentiment leans bullish with 65% buy ratings, but news highlights fuel cost pressures and Boeing MAX 10 certification delays as near-term concerns.
The stock presents a value opportunity given low valuations and robust cash flow, but investors face headwinds from oil price volatility and operational challenges. Upside hinges on Q3 earnings beat and cost management, while downside risks include prolonged certification delays and weaker winter traffic. Institutional ownership trends and dividend stability ($0.44 upcoming) provide support, but macro uncertainties warrant caution.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
